Mark Dehring - CSL Head of Investor Relations

All Insiders . USA . 
Stock . CSL . Stakeholders . Insider . Mark Dehring
CSLLY Stock  USD 91.19  0.89  0.99%   

Executive

Mark Dehring is Head of Investor Relations of CSL since 2014.
Tenure 10 years
Phone61 3 9389 1911
Webhttps://www.csl.com.au

CSL Management Efficiency

The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1338 %, meaning that it generated $0.1338 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities.
CSL has accumulated 3.86 B in total debt with debt to equity ratio (D/E) of 0.66, which is about average as compared to similar companies. CSL has a current ratio of 2.27, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist CSL until it has trouble settling it off, either with new capital or with free cash flow. So, CSL's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CSL sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CSL to invest in growth at high rates of return. When we think about CSL's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Carsten BoessKiniksa Pharmaceuticals
58
Daniel SteinerMolecular Partners AG
N/A
Deborah JDNuvalent
48
Rachel FrankKiniksa Pharmaceuticals
N/A
Gopi MBALarimar Therapeutics
53
Hayley ParkerPepGen
N/A
Sanam JDACELYRIN, INC Common
N/A
Dana PharmDCogent Biosciences
N/A
Catherine MDSyndax Pharmaceuticals
52
Paul KassnerRAPT Therapeutics
57
Steve YoungRAPT Therapeutics
N/A
Evan JDCogent Biosciences
44
Robert HendriksMolecular Partners AG
N/A
Sheila MDVentyx Biosciences
54
Jennifer JohanssonLarimar Therapeutics
N/A
Tyler MarciniakACELYRIN, INC Common
N/A
Sr DOLarimar Therapeutics
63
Cindy BerejikianMineralys Therapeutics, Common
N/A
Amy CFACaribou Biosciences
N/A
Mei JangKiniksa Pharmaceuticals
N/A
Jessica IbbitsonMineralys Therapeutics, Common
N/A
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia. Csl operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 30000 people. CSL [CSLLY] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.13
Return On Asset0.0613

CSL Leadership Team

Elected by the shareholders, the CSL's board of directors comprises two types of representatives: CSL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSL. The board's role is to monitor CSL's management team and ensure that shareholders' interests are well served. CSL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSL's outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul McKenzie, Chief Officer
BCom BComm, Chief Officer
Wilfried Freudenberg, Department Production
Christina Hickie, Sr Communications
BS BS, Exec Counsel
MS BA, Ex Officer
Karen Etchberger, Executive VP of Quality and Bus. Services
Paul BA, CEO MD
Jemimah Brennan, Head Pacific
Mark Dehring, Head of Investor Relations

CSL Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CSL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.13
Return On Asset0.0613
Profit Margin0.18 %
Operating Margin0.25 %
Current Valuation96.65 B
Shares Outstanding964.43 M
Shares Owned By Institutions0.07 %
Price To Earning34.45 X
Price To Book6.77 X
Price To Sales9.04 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for CSL Pink Sheet Analysis

When running CSL's price analysis, check to measure CSL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CSL is operating at the current time. Most of CSL's value examination focuses on studying past and present price action to predict the probability of CSL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CSL's price. Additionally, you may evaluate how the addition of CSL to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY